13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001839435
Total reported value
$1.1B
$1.1B
30 檔
15.3%
The Q2 2025 SEC filing reveals that Octagon Capital Advisors LP held a total portfolio value of $1.1B, covering 30 public equity positions.
In Q2 2025, Octagon Capital Advisors LP adopted a defensive or profit-taking posture, trimming 12 positions and completely liquidating 7 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 9.57% | -1.94% | — | |
| 2 | AVBP | Arrivent Biopharma Inc | Stock-Other | 9.30% | +1.12% | -5.50% | |
| 3 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 7.00% | — | +55.11% | |
| 4 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 6.38% | +1.55% | +17.69% | |
| 5 | SPRY | Ars Pharmaceuticals Inc | Stock-Other | 5.17% | — | +116.00% | |
| 6 | GOSS | Gossamer Bio Inc | Stock-Other | 4.95% | -0.17% | — | |
| 7 | OCUL | Ocular Therapeutix Inc | Stock-Other | 4.94% | -1.14% | — | |
| 8 | ✓ | Merus N V | Stock-Other | 4.49% | — | +26.30% | |
| 9 | TRVI | Trevi Therapeutics Inc | Stock-Other | 4.41% | -1.43% | +10.54% | |
| 10 | COGT | Cogent Biosciences Inc | Stock-Other | 4.35% | -1.84% | — | |
| 11 | ATYR | Atyr Pharma Inc | Stock-Other | 4.25% | — | +7.54% | |
| 12 | APLSUSD | Apellis Pharmaceuticals Inc | Stock-Other | 3.43% | — | -56.85% | |
| 13 | NUVB | Nuvation Bio Inc | Stock-Other | 3.29% | — | -2.64% | |
| 14 | TRML | Tourmaline Bio Inc | Stock-Other | 3.18% | — | — | |
| 15 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 3.16% | -3.23% | EXIT | |
| 16 | BRD1EUR | Mind Medicine Mindmed Inc | Stock-Other | 3.03% | — | -29.42% | |
| 17 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 2.97% | -3.30% | EXIT | |
| 18 | PHVS | Pharvaris N.V. | Stock-Other | 2.60% | +0.90% | -12.63% | |
| 19 | KYMR | Kymera Therapeutics Inc | Stock-Other | 2.55% | -0.72% | — | |
| 20 | ABVX | Abivax Sa-adr | Stock-Other | 2.13% | +3.55% | +3.01% | |
| 21 | DBVT | Dbv Technologies Sa-spon Adr | Stock-Other | 2.04% | -0.48% | — | |
| 22 | CRBP | Corbus Pharmaceuticals Holdi | Stock-Other | 1.69% | — | — | |
| 23 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 1.53% | — | -50.00% | |
| 24 | UNCY | Unicycive Therapeutics Inc | Stock-Other | 1.05% | -0.31% | — | |
| 25 | NGNE | Neurogene Inc | Stock-Other | 0.99% | — | — | |
| 26 | ✓ | Helix Acquisition CORP Ii | Stock-Other | 0.58% | — | — | |
| 27 | MAZE | Maze Therapeutics Inc | Stock-Other | 0.48% | — | -62.04% | |
| 28 | KLRS | Kalaris Therapeutics Inc | Stock-Other | 0.21% | — | -25.16% | |
| 29 | ERAS | Erasca Inc | Stock-Other | 0.20% | — | -86.37% | |
| 30 | NUVB-WS | Nuvation Bio Inc -cw27 | Stock-Other | 0.07% | — | -99.44% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | VRNA | Verona Pharma PLC - Adr | +4.3% | +55.11% | Add |
| 2 | SPRY | Ars Pharmaceuticals Inc | +3.7% | +116.00% | Add |
| 3 | TSHA | Taysha Gene Therapies Inc | +3.5% | +17.69% | Add |
| 4 | KYMR | Kymera Therapeutics Inc | +2.6% | NEW | New buy |
| 5 | ATYR | Atyr Pharma Inc | +2.2% | +7.54% | Add |
| 6 | DBVT | Dbv Technologies Sa-spon Adr | +2% | NEW | New buy |
| 7 | ✓ | Merus N V | +2% | +26.30% | Add |
| 8 | AVBP | Arrivent Biopharma Inc | +1.9% | -5.50% | Trim |
| 9 | OCUL | Ocular Therapeutix Inc | +1.5% | — | Unchanged |
| 10 | DNTH | Dianthus Therapeutics Inc | +1.4% | — | Unchanged |
| 11 | COGT | Cogent Biosciences Inc | +1.2% | — | Unchanged |
| 12 | UNCY | Unicycive Therapeutics Inc | +1.1% | NEW | New buy |
| 13 | GOSS | Gossamer Bio Inc | +1% | — | Unchanged |
| 14 | ABVX | Abivax Sa-adr | +0.6% | +3.01% | Add |
| 15 | NUVB | Nuvation Bio Inc | +0.6% | -2.64% | Trim |
| 16 | CRBP | Corbus Pharmaceuticals Holdi | +0.5% | — | Unchanged |
| 17 | TRML | Tourmaline Bio Inc | +0.5% | — | Unchanged |
| 18 | TRVI | Trevi Therapeutics Inc | +0.4% | +10.54% | Add |
| 19 | NGNE | Neurogene Inc | +0.3% | — | Unchanged |
| 20 | PHVS | Pharvaris N.V. | +0.3% | -12.63% | Trim |
| 21 | 4XC1 | Kalvista Pharmaceuticals Inc | +0.1% | -7.06% | Trim |
| 22 | ✓ | Helix Acquisition CORP Ii | 0% | — | Unchanged |
| 23 | BRD1EUR | Mind Medicine Mindmed Inc | -0.4% | -29.42% | Trim |
| 24 | MAZE | Maze Therapeutics Inc | -0.5% | -62.04% | Trim |
| 25 | KLRS | Kalaris Therapeutics Inc | -0.5% | -25.16% | Trim |
| 26 | MLTX | Moonlake Immunotherapeutics | -0.7% | -50.00% | Trim |
| 27 | CATX | Perspective Therapeutics Inc | -0.9% | EXIT | Sold out |
| 28 | ✓ | -1.1% | EXIT | Sold out | |
| 29 | ERAS | Erasca Inc | -1.2% | -86.37% | Trim |
| 30 | VRDN | Viridian Therapeutics Inc | -1.2% | EXIT | Sold out |
| 31 | RGLS | Regulus Therapeutics Inc | -1.6% | EXIT | Sold out |
| 32 | VSTM | Verastem Inc | -2% | EXIT | Sold out |
| 33 | SRRK | Scholar Rock Holding CORP | -2.1% | EXIT | Sold out |
| 34 | SNDX | Syndax Pharmaceuticals Inc | -2.2% | EXIT | Sold out |
| 35 | 260 | Centessa Pharmaceuticals-adr | -2.7% | -49.14% | Trim |
| 36 | APLSUSD | Apellis Pharmaceuticals Inc | -5.4% | -56.85% | Trim |
| 37 | NUVB-WS | Nuvation Bio Inc -cw27 | -9.2% | -99.44% | Trim |
According to official SEC Form 13F filings, Octagon Capital Advisors LP reported a total U.S. public equity portfolio value of $1.1B across 30 disclosed positions in Q2 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including DNTH, AVBP, VRNA) accounted for 15.3% of total reported equity market value during Q2 2025.
Top New Position Initiated
KYMR
市值: $11.6M
Top Position Liquidated / Trimmed
SNDX
前期市值: $11.1M
During Q2 2025, Octagon Capital Advisors LP's top holdings by market value included DNTH (9.6%)、AVBP (9.3%)、VRNA (7.0%). The largest single position, DNTH, represented 9.6% of total portfolio value.
In Q2 2025, Octagon Capital Advisors LP made 29 total portfolio adjustments, initiating 3 new buys, adding to 7 positions, trimming 12 holdings, and fully liquidating 7 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.